Cardiac Imaging in the VALOR-HCM Trial

Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals

المحتوى المقدم من Cleveland Clinic Heart & Vascular Institute, Cleveland Clinic Heart, and Vascular Institute. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Cleveland Clinic Heart & Vascular Institute, Cleveland Clinic Heart, and Vascular Institute أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

2M ago 31:28

MP3•منزل الحلقة

Mavacamten is the first and only FDA-approved cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (HCM). An important factor to the success of the VALOR HCM trial was the participation of specialized cardiac sonographers and imagers.
Milind Desai, MD, MBA speaks with Jeanne Drinko, Amy Kanta and Anne Campbell about the importance of cardiac imaging.
Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research
Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET), toll-free 800.223.2273, ext. 49162

302 حلقات

#Fitness #Cardiac Consult: For Healthcare Professionals #Cleveland Clinic #Vascular Institute #Cleveland Clinic Heart #Health Industry #Health and Well-Being #Health Care